Sort   by:  
 Page size 
ProteomicsRNF41 regulation of the dendritic cell receptor Clec9A
The dendritic cell receptor Clec9A facilitates processing of dead cell-derived antigens for cross-presentation and the induction of effective CD8+ T cell immune responses. This study investigates the role of E3 ubiquitin ligase RNF41 in Clec9A-mediated ubiquitination, and Clec9A-interactions.
ORGANISM(S): Homo sapiens (Human) 
2020-11-27 | PXD018926 | Pride
Rnf41 E3 ubiquitin ligase Ubiquitination Clec9a 
GenomicsLandscape of protein SUMOylation on chromatin in hIPSCs (ChiPS4) by SUMO1 CHIP-seq
SUMO1 CHIP-seq experiment was performed in untreated hiPSC line - ChiPS4, to determine the exact locations of chromatin bound SUMO1 in these cells, thus providing information about the landscape of SUMOylation of protein targets on chromatin in human pluripotent cells and as such allowing for invest...
ORGANISM(S): Homo sapiens 
2022-12-01 | E-MTAB-9960 | biostudies-arrayexpress
TranscriptomicsInfluence of SUMOylation on transcriptional signature of hIPSCs (ChiPS4) assessed by time-resolved RNA-seq in response to ML792 treatment
SUMOylation is thought to regulate chromatin structure and accessibility thus affecting gene expression. In order to assess these potential roles of SUMOylation in human pluripotent stem cells, ChiPS4 cells were treated with ML792 (selective SUMO E1 inhibitor) or DMSO (vehicle control) for the follo...
ORGANISM(S): Homo sapiens 
2022-12-01 | E-MTAB-9962 | biostudies-arrayexpress
UnknownAnthropometric standardisation and quality control protocols for the construction of new, international, fetal and newborn growth standards: the INTERGROWTH-21st Project.
Not available
S-EPMC4019016 | biostudies-literature
UnknownRNF41 regulates the damage recognition receptor Clec9A and antigen cross-presentation in mouse dendritic cells.
Not available
S-EPMC7710356 | biostudies-literature
UnknownNMDA receptor gene variations as modifiers in Huntington disease: a replication study.
Not available
S-EPMC3186947 | biostudies-literature
UnknownFatal and Nonfatal Events Within 14 days After Early, Intensive Mobilization Poststroke.
Not available
S-EPMC8055346 | biostudies-literature
UnknownFrailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Not available
S-EPMC11390031 | biostudies-literature
UnknownEmpagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483 | biostudies-literature
UnknownHigher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC11872607 | biostudies-literature
Sort   by:  
 Page size